Oral Polio Vaccine (OPV): Advantages, Risks, and Role in Global Eradication

OPV (Sabin) uses live-attenuated poliovirus (types 1, 2, 3) administered orally. It has been instrumental in global polio eradication efforts.

Key Advantages

  • Ease of Delivery: No needles; cold chain simpler than IPV; community health workers can administer.
  • Mucosal Immunity: Induces secretory IgA in the gut, blocking fecal-oral transmission (critical for eradication).
  • Herd Immunity: Vaccine virus spreads to contacts, amplifying population immunity.
  • Cost: ~$0.15–0.20/dose vs. IPV $1–3.
  • Rapid Protection: Single dose induces immunity within days.

Critical Risk: VAPP

  • Vaccine-associated paralytic poliomyelitis: ~1 case per 2.7 million doses (first dose higher risk).
  • Immunodeficiency can lead to prolonged excretion and vaccine-derived poliovirus (VDPV) emergence.

Global Policy Shift

  • 2016 "The Switch": Trivalent OPV (tOPV) → bivalent OPV (bOPV, types 1+3 only) after type 2 eradication certified.
  • Endgame: Sequential IPV → OPV cessation. IPV now in routine immunization globally; OPV reserved for outbreak response (mOPV2, nOPV2).
  • nOPV2 (novel OPV type 2): Genetically stabilized, lower reversion risk.

OPV remains essential for outbreak control in endemic/outbreak zones despite VAPP risk.

Folk Medicine - Related Articles